The majority of newly diagnosed patients with PNH did not receive a PNH-specific therapy at diagnosis. Levels of lactate dehydrogenase significantly predicted fatigue and QOL in patients with PNH after C5 inhibitor therapy. Danicopan added to C5 inhibitor therapy led to significantly improved hemoglobin concentrations in patients with PNH. Pozelimab plus cemdisiran achieved intravascular hemolysis control in patients with paroxysmal nocturnal hemoglobinuria. The FDA has accepted the BLA for crovalimab, an investigational treatment for paroxysmal nocturnal hemoglobinuria. Iptacopan, a complement factor B inhibitor, was effective in patients with PNH with active hemolysis despite eculizumab use. Take a look at these important studies relevant to anemia, venous thromboembolism, sickle cell disease, and PNH. A study assessed survival and adverse events in patients with PNH treated with eculizumab. Pegcetacoplan is a cost-effective alternative for the treatment of paroxysmal nocturnal hemoglobinuria. The U.S. FDA has accepted a Biologics License Application for a novel drug to treat paroxysmal nocturnal hemoglobinuria.